MD ANDERSON THERAPEUTICS DISCOVERY DIVISION
Within The University of Texas MD Anderson Cancer Center lies a powerful engine driving the future of new targeted, immune- and cell-based therapies: the Therapeutics Discovery Division. Therapeutics Discovery eliminates the bottlenecks that hamper traditional drug discovery, with a multidisciplinary team of dedicated researchers, doctors, drug developers and scientific experts working together to develop small-molecule drugs, biologics and cellular therapies. Our unique structure and collaborative approach allow the team to work with agility, bringing novel medicines from concept to clinic quickly and efficiently - all under the same roof.
The Therapeutics Discovery Division is built around four platforms: The Institute for Applied Cancer Science (IACS), ORBIT (Oncology Research for Biologics and Immunotherapy Translation), TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) and the Neurodegeneration Consortium.
The IACS platform is focused on discovering and developing the next generation of small-molecule targeted therapies, driven by the needs we see in our patients. The team aligns world-class drug discovery and development research with the science and clinical care for which MD Anderson is known. We work in a fast-paced, milestone-driven environment with a focus on team science and interdisciplinary research. Our unique approach has created a biotech-like engine within the walls of the nation's leading cancer center to bring life-saving medicines to our patients more quickly and effectively. This model already has achieved results, with multiple programs currently in clinical and late-stage preclinical development.
The Institute Associate Scientist II in the structural chemistry group of the Institute for Applied Cancer Science (IACS) participates in cross-functional research to advance our drug discovery projects from early exploratory efforts through lead optimization, ultimately delivering therapeutic agents of benefit to patients. As part of the IACS team, the Institute Associate Scientist II will deliver high-quality protein samples for a variety of crucial applications, including in vitro assays, X-ray crystallography, and cryo-electron microscopy.
By joining the Therapeutics Discovery Division, you have the opportunity to use your talents to make a direct impact on the lives of our patients. We are seeking a highly motivated and collaborative individual to become a part of our team. The ideal candidate will have experience expressing and purifying recombinant proteins in one or more expression systems.
- Under moderate supervision, conduct laboratory experiments to express, purify, and characterize recombinant proteins to advance IACS projects.
- Conduct test expression experiments to identify optimal expression system (eg. E. coli, insect cell, mammalian) and conditions for protein production.
- Express recombinant proteins at multi-liter scale in an appropriate expression system.
- Purify proteins using Bio-Rad NGC FPLCs.
- Characterize purified proteins using biophysical methods (eg. nanoDSF, dynamic light scattering, ITC) to ensure suitable quality for downstream applications (eg. in vitro assays, structural biology).
- Presents research results to integrated drug discovery research project teams.
- Employ safe lab practices.
- Maintain research records and laboratory notes.
Required: Bachelor's degree in Biology, Biochemistry, Molecular Biology, Cell Biology, Enzymology, Pharmacology, Chemistry or related field.
Education Preferred: Master's degree in Biology, Biochemistry, Molecular Biology, Cell Biology, Enzymology, Pharmacology, Chemistry or related field.
Required: One year of relevant research experience in lab. With preferred degree, no required experience.
Preferred: Experience expressing recombinant proteins from E. coli, insect cell, or mammalian cell systems. Experience with FPLC-based protein purification instruments. Excellent communication, writing and organizational skills.
It is the policy of The University of Texas MD Anderson Cancer Center to provide equal employment opportunity without regard to race, color, religion, age, national origin, sex, gender, sexual orientation, gender identity/expression, disability, protected veteran status, genetic information, or any other basis protected by institutional policy or by federal, state or local laws unless such distinction is required by law. http://www.mdanderson.org/about-us/legal-and-policy/legal-statements/eeo-affirmative-action.html